Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$34.26M+582.65%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason A. Breaux
- Sector
- Financial Services
- Industry
- Asset Management
- Employees
- 250
- Beta
- 0.60
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 0.17
Financials
Revenue
$34.26M+582.7%Net Income
$10.11M+132.3%EBITDA
$25.41M+613.6%Free Cash Flow
$24.41MEPS (diluted)
$0.27-62.0%Shares Outstanding (diluted)
36.85M+504.8%Operating Expenses
$1.35MCash & Debt
$12.08MReturn of Capital
$13.63MDividend per Share
$0.34Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $156.19M | $34.51M | $0.93 |
| 2024 | $142.44M | $73.65M | $1.99 |
| 2023 | $147.33M | $83.84M | $2.33 |
| 2022 | $52.10M | $15.54M | $0.50 |
| 2021 | $101.10M | $83.63M | $2.94 |
| 2020 | $62.02M | $54.67M | $1.98 |
| 2019 | $37.34M | $29.28M | $1.04 |
| 2018 | $15.04M | $8.12M | $0.27 |
| 2017 | $15.77M | $9.06M | $0.30 |
| 2016 | $17.02M | $11.77M | $1.83 |
| 2015 | $245.6K | $-2.16M | $-0.84 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.37
- Implied price
- $20.53
- Return from $9.96
- 15.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $10.21 — today's price is already 2.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -2.0% | -1.4% | 1.9% | 4.9% | 7.5% | 9.9% |
| 3.0% | 3.6% | 7.1% | 10.2% | 13.0% | 15.6% |
| 8.0% | 8.6% | 12.3% | 15.6% | 18.5% | 21.2% |
| 13.0% | 13.6% | 17.5% | 20.9% | 24.0% | 26.8% |
| 18.0% | 18.7% | 22.7% | 26.3% | 29.5% | 32.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
150+127.27%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·12d ago·Neutral
Crescent Capital BDC, Inc. (CCAP) Q3 2026 Earnings Call Transcript Crescent Capital BDC, Inc. ( CCAP ) Q3 2026 Earnings Call November 10, 2026 12:00 PM EST Company Participants Daniel McMahon - Senior VP & Head of Public Investor Relations Jason Breaux - CEO & Chairman of the Board Gerhard Lombard - Chief Financial Officer Henry Chung - President & Director Conference Call Participants Christopher Nolan - Ladenburg Thalmann & Co. Inc., Research Division Finian O'Shea - Wells Fargo Securities, LL…
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
What Crescent Capital BDC (CCAP) Said on Its Q3 Earnings Call Crescent Capital BDC NASDAQ: CCAP reported a slight increase in third-quarter investment income and announced plans to buy back shares and form a joint venture as it works to reduce leverage.
View source ↗ - Newszacks.com·13d ago·Positive
Crescent Capital BDC (CCAP) Surpasses Q3 Earnings and Revenue Estimates Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.46 per share a year ago.
View source ↗ - Newsseekingalpha.com·60d ago·Positive
Crescent Capital: Coverage Restoration, Fee Reduction And Rate Hikes Are Catalysts Crescent Capital is upgraded from ‘Buy' to ‘Strong Buy' due to improved dividend coverage and a compelling valuation. CCAP's 19% dividend cut enhanced coverage, with Q2 net investment income covering the dividend at 106%. Management lowered both management and incentive fees, further supporting future dividend stability and income profile.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Crescent Capital BDC, Inc. (CCAP) Q2 2026 Earnings Call Transcript Crescent Capital BDC, Inc. (CCAP) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·104d ago·Negative
Crescent Capital BDC (CCAP) Misses Q2 Earnings and Revenue Estimates Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.46 per share a year ago.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $0.36 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$0.37 vs $0.35beat
- Mon, Aug 10$0.36 vs $0.37miss
- Wed, May 13$0.42 vs $0.41beat
- Wed, Feb 25$0.45 vs $0.44beat
- Wed, Nov 12$0.46 vs $0.46miss
- Wed, Aug 13$0.46 vs $0.46beat
Estimates and results for CCAP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CCAP officers and directors.
- Bought
- $1.9m
- Sold
- $5.6m
24 trades
13 trades
- Breaux Jasonbought
- Lombard Gerhardbought
- Fidelity & Guaranty Life Insurance Cosold
- Fidelity & Guaranty Life Insurance Cosold
- Fidelity & Guaranty Life Insurance Cosold
- Fidelity & Guaranty Life Insurance Cosold
- Fidelity & Guaranty Life Insurance Cosold
- Fidelity & Guaranty Life Insurance Cosold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CCAP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
